Latest news

The future of precision cancer medicine

The first national initiatives for precision cancer medicine have successfully taken shape in Norway, but what has been achieved and what do

CONNECT grows to 30 partners

CONNECT welcomes the two new partners Gilead Sciences Nordic Region and the Norwegian Directorate for E-health.

CONNECT seminar on Digital Pathology and AI

Experts from regional, national and international groups shared their perspectives on digital pathology and artificial intelligence (AI)...

Norwegian cancer initiatives receive international attention

Norway is pioneering precision medicine in cancer with three nation-wide initiatives.

CONNECT seminar om Nukleærmedisin

Nukleærmedisin med presisjonsdiagnostikk og persontilpasset behandling. Nukleærmedisin omfatter både diagnostikk og behandling ved bruk...

GSK is CONNECT's 6th new partner in 2021, and sponsor of the Cancer Crosslinks 2022

CONNECT’s newest partner, GSK, sponsors the Cancer Crosslinks 2022, and is increasing its focus on oncology and hematology. These are...

CONNECT Seminar on Clinical Decision Support Systems

Clinical Decision Support Systems: useful for what and for whom? In his introduction, Eivind Hovig, Professor at the Centre for...

CONNECT's partner, Eli Lilly & Company, is now part of the IMPRESS study

CONNECTs partner Eli Lilly & Company is now offering participants of the IMPRESS study a new and promising medicine.

CONNECT seminar: The new EU regulations on IVDR – how to be prepared?